NRX Pharmaceuticals, Inc. — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
NRx Defense Systems, a subsidiary of NRx Pharmaceuticals (market cap ~$57.4M), was awarded an $11,177,757 DARPA contract to conduct the SPARC-TMS clinical trial testing robotic transcranial magnetic stimulation combined with NRX-101 for treatment-resistant depression. The trial, approved by FDA (NCT07227103), will be conducted at Harvard Medical School's McLean Hospital, Arizona State University, and HOPE Therapeutics, with potential expansion to military hospitals. If successful, the trial could serve as an FDA registration study for NRX-101 combined with TMS, targeting the 8.9 million American adults with treatment-resistant depression.
Why this rating
Contract value (~$11.2M) equals 19% of company market cap—material near-term cash inflow. FDA-approved trial with potential registration pathway significantly de-risks NRX-101 approval. DARPA backing and military focus open new market segment. However, clinical trial outcomes remain unproven.
Price action (we called it positive)
before filing · preread $2.86 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.